Wealthfront Advisers LLC Has $1.31 Million Stock Holdings in Insulet Corporation (NASDAQ:PODD)

Wealthfront Advisers LLC lowered its position in Insulet Corporation (NASDAQ:PODD - Free Report) by 15.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,974 shares of the medical instruments supplier's stock after selling 917 shares during the quarter. Wealthfront Advisers LLC's holdings in Insulet were worth $1,306,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in PODD. Allspring Global Investments Holdings LLC grew its position in shares of Insulet by 55.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier's stock valued at $1,376,000 after buying an additional 1,867 shares during the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Insulet by 85.1% in the 1st quarter. Farther Finance Advisors LLC now owns 896 shares of the medical instruments supplier's stock worth $236,000 after acquiring an additional 412 shares during the period. QRG Capital Management Inc. boosted its position in shares of Insulet by 75.6% during the 1st quarter. QRG Capital Management Inc. now owns 2,030 shares of the medical instruments supplier's stock valued at $533,000 after purchasing an additional 874 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new position in shares of Insulet during the 4th quarter valued at about $9,822,000. Finally, Exchange Traded Concepts LLC boosted its position in shares of Insulet by 225.4% during the 1st quarter. Exchange Traded Concepts LLC now owns 1,552 shares of the medical instruments supplier's stock valued at $408,000 after purchasing an additional 1,075 shares in the last quarter.

Insider Activity at Insulet

In other Insulet news, SVP John W. Kapples sold 5,278 shares of the company's stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the transaction, the senior vice president directly owned 23,180 shares in the company, valued at $7,382,134.60. The trade was a 18.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.39% of the stock is currently owned by corporate insiders.

Insulet Stock Up 0.4%

Shares of NASDAQ PODD traded up $1.10 during midday trading on Wednesday, reaching $286.67. The company's stock had a trading volume of 583,567 shares, compared to its average volume of 717,850. The company has a current ratio of 4.47, a quick ratio of 3.63 and a debt-to-equity ratio of 1.21. Insulet Corporation has a fifty-two week low of $173.00 and a fifty-two week high of $329.33. The stock has a market capitalization of $20.18 billion, a price-to-earnings ratio of 51.56, a PEG ratio of 2.55 and a beta of 1.35. The stock has a 50 day simple moving average of $307.78 and a 200-day simple moving average of $281.29.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, topping analysts' consensus estimates of $0.81 by $0.21. The business had revenue of $569.00 million for the quarter, compared to the consensus estimate of $543.20 million. Insulet had a net margin of 18.29% and a return on equity of 22.25%. The firm's revenue for the quarter was up 28.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.73 earnings per share. Equities research analysts predict that Insulet Corporation will post 3.92 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Wolfe Research upgraded shares of Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price target for the company in a research report on Tuesday, May 13th. The Goldman Sachs Group assumed coverage on shares of Insulet in a research note on Friday, May 30th. They set a "buy" rating and a $380.00 price target on the stock. Sanford C. Bernstein reissued an "outperform" rating on shares of Insulet in a research report on Friday, May 16th. Wells Fargo & Company set a $322.00 price target on shares of Insulet in a report on Monday, April 28th. Finally, Oppenheimer increased their price target on shares of Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Four equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $321.00.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.